ASCO 2022 | Adjuvant therapy in RCC: harnessing prognostic information

Pavlos Msaouel, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses value-based decision making in the adjuvant setting for patients with renal cell carcinoma (RCC), highlighting the importance of understanding which patients are more likely to respond to adjuvant treatment approaches by harnessing prognostic risk information. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.